Cargando…
A novel CAR-T cell product targeting CD74 is an effective therapeutic approach in preclinical mantle cell lymphoma models
BACKGROUND: Mantle cell lymphoma (MCL) is a rare B-cell non-Hodgkin lymphoma subtype which remains incurable despite multimodal approach including chemoimmunotherapy followed by stem cell transplant, targeted approaches such as the BTK inhibitor ibrutinib, and CD19 chimeric antigen receptor (CAR) T...
Autores principales: | Chan, Wing Keung, Williams, Jessica, Sorathia, Kinnari, Pray, Betsy, Abusaleh, Kaled, Bian, Zehua, Sharma, Archisha, Hout, Ian, Nishat, Shamama, Hanel, Walter, Sloan, Shelby L., Yasin, Aneeq, Denlinger, Nathan, Zhang, Xiaoli, Muthusamy, Natarajan, Vasu, Sumithira, de Lima, Marcos, Yang, Yiping, Baiocchi, Robert, Alinari, Lapo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10517521/ https://www.ncbi.nlm.nih.gov/pubmed/37740214 http://dx.doi.org/10.1186/s40164-023-00437-8 |
Ejemplares similares
-
Novel targeted therapies for mantle cell lymphoma
por: Alinari, Lapo, et al.
Publicado: (2012) -
Evaluating the Therapeutic Potential of Zanubrutinib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma: Evidence to Date
por: Sawalha, Yazeed, et al.
Publicado: (2020) -
A sumoylation program is essential for maintaining the mitotic fidelity in proliferating mantle cell lymphoma cells
por: Hanel, Walter, et al.
Publicado: (2022) -
Exploiting the fibroblast growth factor receptor-1 vulnerability to therapeutically restrict the MYC-EZH2-CDKN1C axis-driven proliferation in Mantle cell lymphoma
por: Sircar, Anuvrat, et al.
Publicado: (2023) -
Inhibition of SRC-3 as a potential therapeutic strategy for aggressive mantle cell lymphoma
por: Bijou, Imani, et al.
Publicado: (2023)